DNA Damage by Tumor Cell-Specific N-Oxides

肿瘤细胞特异性氮氧化物对 DNA 的损伤

基本信息

  • 批准号:
    6602990
  • 负责人:
  • 金额:
    $ 17.04万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2003
  • 资助国家:
    美国
  • 起止时间:
    2003-03-14 至 2007-02-28
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): 3-Amino-1,2,4-benzotriazine 1,4-dioxide (tirapazamine, TPZ) is a bioreductively-activated DNA-damaging agent that selectively kills the hypoxic cells found in virtually all solid tumors. This compound shows great clinical promise and is currently being examined in more than ten different clinical trials, including several phase III studies. Importantly, TPZ damages DNA via a completely novel sequence of chemical reactions in which the one-electron reduced drug initiates radical-mediated DNA damage and then the drug or its metabolites transfer oxygen atoms from their N-oxide functional groups to the resulting DNA radicals, thus, converting them to strand cleavage sites. While the medicinal properties of TPZ have been extensively investigated, many of its biologically relevant chemical properties remain poorly understood. The growing clinical interest in TPZ provides a practical incentive to characterize the relevant chemistry of this drug. In addition, characterization of this new chemical motif that efficiently delivers cytotoxic DNA-damaging radicals to the interior of hypoxic cells may be of fundamental interest in both medicinal chemistry and toxicology. The work described in this proposal is divided into three Specific Aims: 1. How does TPZ generate radical lesions on DNA? Does the drug serve to deliver the known DNA-damaging agent hydroxyl radical to hypoxic cells? How do the conditions of low oxygen and low pH found in tumor cells combine to facilitate DNA damage by the drug? 2. What is the chemical mechanism by which TPZ and its metabolites transfer oxygen atoms from their N-oxide functional groups to DNA radicals? This unprecedented reaction allows the drug to efficiently damage DNA under hypoxic conditions and may play a central role in defining the structural nature of the final DNA lesions caused by TPZ. 3. We propose studies to characterize the structural nature of the DNA strand breaks and base damage mediated by TPZ. These studies will explore the possibility that the unusual conditions under which TPZ operates, along with the unique chemical properties of the drug, lead to a unique spectrum of DNA lesions that confront cells with social challenges to their DNA-repair systems.
描述(由申请人提供):3-氨基-1,2,4-苯并三嗪1,4-二氧化(替拉帕嗪,TPZ)是一种生物还原激活的dna损伤剂,可以选择性地杀死几乎所有实体肿瘤中的缺氧细胞。该化合物显示出巨大的临床前景,目前正在进行十多项不同的临床试验,包括几项III期研究。重要的是,TPZ通过一系列全新的化学反应破坏DNA,其中单电子还原药物引发自由基介导的DNA损伤,然后药物或其代谢物将氧原子从其n -氧化物官能团转移到产生的DNA自由基上,从而将它们转化为链切割位点。虽然TPZ的药用特性已被广泛研究,但其许多生物学相关的化学特性仍然知之甚少。对TPZ日益增长的临床兴趣提供了一个实际的激励来表征该药物的相关化学。此外,表征这种新的化学基序,有效地将细胞毒性dna损伤自由基传递到缺氧细胞内部,可能是药物化学和毒理学的基本兴趣。本提案所描述的工作分为三个具体目标:1。TPZ是如何在DNA上产生根治性损伤的?这种药物是否可以将已知的dna损伤剂羟基自由基传递到缺氧细胞中?肿瘤细胞中的低氧和低pH值是如何结合起来促进药物对DNA的损伤的?2. TPZ及其代谢物将氧原子从n -氧化物官能团转移到DNA自由基的化学机制是什么?这种前所未有的反应使药物能够在缺氧条件下有效地破坏DNA,并可能在确定TPZ引起的最终DNA损伤的结构性质方面发挥核心作用。3. 我们建议研究表征TPZ介导的DNA链断裂和碱基损伤的结构性质。这些研究将探索TPZ在不寻常条件下运作的可能性,以及该药物独特的化学性质,导致独特的DNA损伤光谱,使细胞面临DNA修复系统的社会挑战。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Kent S Gates其他文献

DNA-catalyzed hydrolysis of DNA phosphodiesters
DNA 催化的 DNA 磷酸二酯水解
  • DOI:
    10.1038/nchembio.224
  • 发表时间:
    2009-10-01
  • 期刊:
  • 影响因子:
    13.700
  • 作者:
    Mostafa I Fekry;Kent S Gates
  • 通讯作者:
    Kent S Gates
FaPy lesions and DNA mutations
法氏囊病变和 DNA 突变
  • DOI:
    10.1038/nchembio.1274
  • 发表时间:
    2013-06-17
  • 期刊:
  • 影响因子:
    13.700
  • 作者:
    Kent S Gates
  • 通讯作者:
    Kent S Gates

Kent S Gates的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Kent S Gates', 18)}}的其他基金

Cross-links at abasic sites in duplex DNA
双链 DNA 脱碱基位点的交联
  • 批准号:
    10524017
  • 财政年份:
    2012
  • 资助金额:
    $ 17.04万
  • 项目类别:
Cross-links At Abasic Sites in Duplex DNA
双链 DNA 中无碱基位点的交联
  • 批准号:
    8664848
  • 财政年份:
    2012
  • 资助金额:
    $ 17.04万
  • 项目类别:
Cross-links At Abasic Sites in Duplex DNA
双链 DNA 中无碱基位点的交联
  • 批准号:
    8867233
  • 财政年份:
    2012
  • 资助金额:
    $ 17.04万
  • 项目类别:
Cross-links At Abasic Sites in Duplex DNA
双链 DNA 中无碱基位点的交联
  • 批准号:
    8372731
  • 财政年份:
    2012
  • 资助金额:
    $ 17.04万
  • 项目类别:
Cross-links at abasic sites in duplex DNA
双链 DNA 脱碱基位点的交联
  • 批准号:
    10295786
  • 财政年份:
    2012
  • 资助金额:
    $ 17.04万
  • 项目类别:
Cross-links at abasic sites in duplex DNA
双链 DNA 脱碱基位点的交联
  • 批准号:
    10054954
  • 财政年份:
    2012
  • 资助金额:
    $ 17.04万
  • 项目类别:
Cross-links At Abasic Sites in Duplex DNA
双链 DNA 中无碱基位点的交联
  • 批准号:
    8531243
  • 财政年份:
    2012
  • 资助金额:
    $ 17.04万
  • 项目类别:
Chemical and Biological Mechanisms of Leinamycin
莱纳霉素的化学和生物学机制
  • 批准号:
    7028123
  • 财政年份:
    2006
  • 资助金额:
    $ 17.04万
  • 项目类别:
Chemical and Biological Mechanisms of Leinamycin
莱纳霉素的化学和生物学机制
  • 批准号:
    7286021
  • 财政年份:
    2006
  • 资助金额:
    $ 17.04万
  • 项目类别:
Conference Grant: "DNA Alkylation: From Natural Products to Chemotherapy"
会议资助:“DNA烷基化:从天然产物到化疗”
  • 批准号:
    7159973
  • 财政年份:
    2006
  • 资助金额:
    $ 17.04万
  • 项目类别:

相似海外基金

DNA repair pathway coordination during damage processing
损伤处理过程中 DNA 修复途径的协调
  • 批准号:
    10748479
  • 财政年份:
    2024
  • 资助金额:
    $ 17.04万
  • 项目类别:
CAREER: Mechanisms and consequences of epigenome-recruited DNA repair systems in plants
职业:植物中表观基因组招募的 DNA 修复系统的机制和后果
  • 批准号:
    2338236
  • 财政年份:
    2024
  • 资助金额:
    $ 17.04万
  • 项目类别:
    Continuing Grant
Multifaceted regulation of the DNA repair machinery and suppression of aberrant transcription by telomere proteins
DNA 修复机制的多方面调控和端粒蛋白异常转录的抑制
  • 批准号:
    2246561
  • 财政年份:
    2023
  • 资助金额:
    $ 17.04万
  • 项目类别:
    Standard Grant
Elucidation of the molecular link between DNA repair and mitochondrial nucleic acid metabolism
阐明DNA修复和线粒体核酸代谢之间的分子联系
  • 批准号:
    23K07078
  • 财政年份:
    2023
  • 资助金额:
    $ 17.04万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
DNA Repair State Machines
DNA 修复状态机
  • 批准号:
    EP/X027406/1
  • 财政年份:
    2023
  • 资助金额:
    $ 17.04万
  • 项目类别:
    Research Grant
Structural studies for understanding the mechanism of DNA repair in chromatin
了解染色质 DNA 修复机制的结构研究
  • 批准号:
    23H05475
  • 财政年份:
    2023
  • 资助金额:
    $ 17.04万
  • 项目类别:
    Grant-in-Aid for Scientific Research (S)
Biochemistry of Eukaryotic Replication Fork and DNA Repair
真核复制叉的生物化学和 DNA 修复
  • 批准号:
    10550045
  • 财政年份:
    2023
  • 资助金额:
    $ 17.04万
  • 项目类别:
Modeling the Responsiveness of Sensitive Populations to Genotoxic Agents Using DNA Repair Inhibitors
使用 DNA 修复抑制剂模拟敏感人群对基因毒性药物的反应性
  • 批准号:
    10734425
  • 财政年份:
    2023
  • 资助金额:
    $ 17.04万
  • 项目类别:
A role of balanced sex hormone in DNA repair in human melanocytes
平衡性激素在人类黑素细胞 DNA 修复中的作用
  • 批准号:
    10666307
  • 财政年份:
    2023
  • 资助金额:
    $ 17.04万
  • 项目类别:
Natural products inhibitors targeting homology-directed DNA repair for cancer therapy
针对癌症治疗的同源定向 DNA 修复的天然产物抑制剂
  • 批准号:
    10651048
  • 财政年份:
    2023
  • 资助金额:
    $ 17.04万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了